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X-linked agammaglobulinemia (XLA) is characterized by a
severe B-cell deficiency, resulting from a differentiation arrest in
the bone marrow (BM). Because XLA is clinically and immu-
nologically heterogeneous, we investigated whether the B-cell
differentiation arrest in BM of XLA patients is heterogeneous as
well. First, we analyzed BM samples from 19 healthy children by
flow cytometry. This resulted in a normal B-cell differentiation
model with eight consecutive stages. Subsequently, we analyzed
BM samples from nine XLA patients. Eight patients had amino
acid substitutions in the Bruton’s tyrosine kinase (BTK) domain
or premature stop codons, resulting in the absence of functional
BTK proteins. In seven of these eight patients a major differen-
tiation arrest was observed at the transition between cytoplasmic
Ig pre-B-I cells and cytoplasmic Ig pre-B-II cells, consis-
tent with a role for BTK in pre-B-cell receptor signaling. How-
ever, one patient exhibited a very early arrest at the transition
between pro-B cells and pre-B-I cells, which could not be
explained by a different nature of the BTK mutation. We con-
clude that the absence of functional BTK proteins generally leads
to an almost complete arrest of B-cell development at the pre-B-I
to pre-B-II transition. The ninth XLA patient had a splice site
mutation associated with the presence of low levels of wild-type
BTK mRNA. His BM showed an almost normal composition of
the precursor B-cell compartment, suggesting that low levels of
BTK can rescue the pre-B-cell receptor signaling defect, but do
not lead to sufficient numbers of mature B lymphocytes in the
peripheral blood. (Pediatr Res 51: 159–168, 2002)
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XLA is a primary immunodeficiency, which affects approx-
imately 1 in 100,000 boys and is characterized by agamma- or
hypogammaglobulinemia and strongly reduced numbers of B
lymphocytes in PB (1). The clinical picture of XLA generally
develops during the first year of life, after maternal antibodies
have disappeared from the serum, with frequent infections of
different organ systems, particularly upper and lower respira-
tory tract and gastrointestinal infections, but also bacterial skin
infections, meningitis, septicemia, or osteomyelitis (1, 2).
XLA is caused by mutations in the gene encoding BTK,
located on Xq21.3 (3, 4). BTK is a cytoplasmic protein of 659
aa, composed of five different domains, the pleckstrin homol-
ogy, Tec homology, Src homology 3, Src homology 2, and
kinase domain (1). So far, 341 unique mutations have been
reported, which are scattered throughout the gene (5). No
correlation has been described between the type and position of
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the mutations and phenotypic variables, such as age or serum
Ig levels at diagnosis or severity of infections (2, 6). XLA is a
heterogeneous disease (7, 8), which could be the result of
differences in mutations in the BTK gene, in combination with
other genetic or environmental factors, infections, or age of the
patients.
Early studies have shown that in XLA a B-cell differentia-
tion arrest occurs in BM (9–11). However, controversy exists
regarding the stage in B-cell development that is primarily
affected by mutations in the BTK gene. Differentiation arrests
have been described between CyIg precursor B cells and
SmIgM immature B cells as well as at the transition of
CyIg into CyIg precursor B cells (10, 11). These findings
could reflect heterogeneity in the stages at which B-cell devel-
opment is arrested, in parallel with the clinical and immuno-
logic heterogeneity of XLA (12–14). In a recent study, MAb
against the surrogate light chains were used to characterize the
differentiation arrest (15). It was shown that the major blockade
in XLA patients was located at the transition from large to
small CyIglow–surrogate light chainbright pre-B cells (15).
However, the authors did not discuss the severity of the
blockade. The severity of this arrest might be variable, because
XLA patients differ in the absolute numbers of mature B
lymphocytes in their PB, which suggests that variable degrees
of leakiness exist (16). The residual B cells can proliferate,
undergo IgH isotype switching, and differentiate into specific
antibody-producing cells (17). We hypothesized that an accu-
rate characterization of the B-cell differentiation arrest in BM
of XLA patients would help to explain the level of immuno-
logic variation and provide information on the function of BTK
in early B-cell development in man.
Several recent flow cytometric studies have shown that in
human BM, five to six B-cell differentiation stages can be
distinguished (18–22). According to Ghia et al. (19, 21),
pro-B, pre-B-I, large pre-B-II, small pre-B-II, immature B, and
mature B cells can be recognized in man on the basis of Ig
rearrangement and cytoplasmic or surface Ig expression. BTK
functions as a signal-transducing element downstream of the
BCR, thereby directing B-cell development (23).
To unravel the precise B-cell differentiation arrest in XLA
patients and to obtain information on the degree of leakiness,
we performed detailed flow cytometric studies of nine BM
samples from XLA patients together with 19 BM samples from
healthy children younger than 16 y of age as controls.
METHODS
Cell samples. We received BM samples from 19 healthy
children (youngest age, 1 y 7 mo; oldest 16 y 1 mo; median, 8 y
2 mo; 10 boys, 9 girls), who were donors for BM transplanta-
tion of their siblings (Department of Pediatrics, Leiden Uni-
versity Medical Center; Drs. P.M. Hoogerbrugge and J.M.J.J.
Vossen). These control BM samples were used for detailed
flow cytometric studies, via the LWBM method (24) as well as
after Ficoll-Paque density centrifugation (density, 1.077 g/mL;
Pharmacia, Uppsala, Sweden).
We received BM and PB samples from nine XLA patients
during the last 15 y. BM samples from four recent XLA
patients were used for flow cytometric analysis according to
the LWBM method. The BM samples from the other five XLA
patients were subjected to Ficoll density centrifugation. The
recovered MC were frozen and stored in liquid nitrogen and
thawed later for flow cytometric immunophenotyping studies.
Granulocytes and MC were isolated from PB by Ficoll
density centrifugation and used for DNA or RNA extraction.
All cell samples were obtained according to the informed
consent guidelines of the Medical Ethics Committees of the
Leiden University Medical Center and the University Hospital
Rotterdam.
Comparison of cell samples. In four healthy children, we
compared the results of flow cytometric analysis of fresh BM
via the LWBM method with the results obtained from thawed
BMMC. Furthermore, in five other healthy children, we com-
pared the results of flow cytometric analysis of fresh BM via
the LWBM method with the results obtained from freshly
isolated BMMC. All flow cytometric data concerning the
precursor B-cell compartment were analyzed independently by
two experienced technicians and did not show significant
changes before and after Ficoll density centrifugation as well
as before and after freezing and thawing of MC, implying that
no major selective loss of particular precursor B-cell subsets
occurred. Moreover, using BMMC from our cell bank (storage
in liquid nitrogen) was the only way we could obtain BM
samples from enough XLA patients to perform this study.
Flow cytometric analysis of BM from healthy children and
XLA patients. BM samples were diluted with PBS (pH7.8) to
a concentration of 15  106 cells/mL. Twenty-five microliter
aliquots of whole BM or BMMC were incubated for 10 min at
Table 1. Triple labelings for analysis of B-cell differentiation
FITC-
conjugates PE-conjugates
PE-Cy5-
conjugates
MAb directed against membrane antigens
1 CD34
(HPCA-2)*
CD22 (Leu-14)* CD19 (HIB19)§
2 CD34
(HPCA-2)
CD10 (J5) CD19 (HIB19)
3 CD34
(HPCA-2)
CD38 (Leu-17)* CD19 (HIB19)
4 CD34
(HPCA-2)
CD20 (Leu-16)* CD19 (HIB19)
5 CD10
(J5)†
CD20 (Leu-16) CD19 (HIB19)
6 SmIgM CD10 (J5) CD19 (HIB19)
7 SmIgD SmIgM (MB-11)‡ CD19 (HIB19)
MAb directed against membrane antigens and TdT via FACS Lysing
Solution
8 TdT (hTdT-6)¶ CD22 (Leu-14) CD19 (HIB19)
9 TdT (hTdT-6) CD34 (HPCA-2) CD19 (HIB19)
10 TdT (hTdT-6) CD10 (J5) CD19 (HIB19)
MAb directed against membrane antigens and CyIg via IntraPrep
11 CyIg CD34 (HPCA-2) CD19 (HIB19)
12 CyIg CD10 (J5) CD19 (HIB19)
13 CyIg CD38 (Leu-17) CD19 (HIB19)
14 CyIg SmIgM (MB-11) CD19 (HIB19)
MAb were derived from * Becton Dickinson (San Jose, CA, U.S.A.);
† Beckman Coulter (Brea, CA, U.S.A.); ‡ Sigma Aldrich (St. Louis, MO,
U.S.A.); § Serotec (Raleigh, NC, U.S.A.);  Kallestad/Sanofi-Synthelabo (Par-
is, France); ¶ Supertechs (Bethesda, MD, U.S.A.).
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room temperature with combinations of optimally titrated
MAb: 25 L FITC-conjugated MAb, or 25 L phycoerythrin-
conjugated MAb, or 25 L PE/Cy5-conjugated Mab, or com-
binations of preceding MAbs were used to detect membrane-
bound antigens. After incubation, the cells were washed and
further processed depending on the type of triple labeling. The
14 applied triple labelings are summarized in Table 1.
Triple labelings for three membrane-bound antigens (label-
ings 1–7 in Table 1) were directly analyzed by flow cytometry
using FACScan (Becton Dickinson, San Jose, CA, U.S.A.) in
case of BMMC, whereas whole BM samples were first sub-
jected to lysis of the erythrocytes using FACS Lysing Solution
(Becton Dickinson).
Permeabilization of the BM cells using FACS Lysing Solu-
tion (Becton Dickinson) was performed before intranuclear
staining of TdT both on whole BM samples and BMMC
(labelings 8–10 in Table 1) (24, 25).
Intracellular staining of Ig (CyIg) was performed after
permeabilization of the BM cells using IntraPrep Permeabili-
zation Reagent (Immunotech, Marseille, France) both on whole
BM samples and BMMC (labelings 11–14 in Table 1) (24, 25).
DNA and RNA extraction and RT reaction. DNA was
extracted from PBMC or granulocytes using the QIAamp
Blood kit (Qiagen, Chatsworth, CA, U.S.A.) (26). Total RNA
was isolated from PB granulocytes according to the method of
Chomczynski and Sacchi (27) using RNAzol B (Tel-Test,
Friendswood, TX, U.S.A.). cDNA was prepared from 1 g of
mRNA as described before, using oligo(dT) and avian myelo-
blastosis virus (AMV) RT (Promega, Madison, WI, U.S.A.)
(28).
PCR amplification of (c)DNA. PCR was performed as
described previously (29). Exons 1–13 and exon 19 of the BTK
gene were amplified separately, whereas exons 14–18 were
amplified in one LR-PCR reaction. In each 100 L of PCR
reaction, 0.1 g of (c)DNA, 20 pmol of 5' and 3' oligonucle-
otides, and 1 U of AmpliTaq gold polymerase (Applied Bio-
systems, Foster City, CA, U.S.A.) were used. PCR conditions
were 2–10 min at 94°C, followed by 60 s at 92°C, 60 s at
57–60°C, and 2 min at 72°C for 40 cycles, followed by a final
extension step (7 min at 72°C).
In each 100 L of LR-PCR reaction, 0.1 g of DNA sample,
5.25 U of Expand enzyme mix (Boehringer Mannheim, Mann-
heim, Germany), and 30 pmol of 5' and 3' oligonucleotides
were used. LR-PCR conditions were 2 min at 94°C, followed
by 15 s at 94°C, 30 s at 57°C, and 4 min at 68°C for 40 cycles
using 10 s autoextension from cycle 21 onward. After the last
cycle an additional step of 10 min at 72°C was performed for
final extension.
The sequences of the oligonucleotides used for PCR ampli-
fication of BTK were based on Oeltjen et al. (30) (Genbank
accession number U78027) and were designed with the
OLIGO 6 program (Dr. W. Rychlik, Molecular Biology In-
sights, Cascade, CO, U.S.A.) (31). Primer sequence data will
be made available on request to interested readers.
Fluorescent sequencing reaction and analysis. LR-PCR
products of BTK exons 14–18 were first purified with the
QIAquick PCR purification kit (Qiagen), whereas short PCR
products (exons 1–13 and 19) were used directly for sequenc-
ing with 5 L of dRhodamine dye terminator mix (Applied
Biosystems), using 3.3 pmol of sequencing primers. The se-
quencing primers were positioned in the BTK introns just
upstream and downstream of the exon-intron borders, so that
Figure 1. Flow cytometric analysis of BM samples from two healthy children
using a mix of PerCP-Cy5.5–labeled MAbs to confirm the reliability of CD22
as a pan-B-cell marker. Flow cytometric analyses within a BM lymphogate
showed that CD22 is rarely expressed on CD3 T cells, CD16 NK cells, or
CD33 myeloid cells, thereby confirming the reliability of CD22 as a pan-B-
cell marker.
Table 2. Composition of the BM lymphogate
CD22 B cells (%) CD3 T
lymphocytes
(%)
CD16/CD56
NK cells (%)
CD13/CD33
myeloid cells
(%)
CD71/GpA/CD45
normoblasts (%)Precursor B cells* Mature B cells†
Healthy children 5 y (n  6) 36  7 12  9 22  13 3  1 6  3 25  16
Healthy children 5–10 y (n  7) 27  9 7  3 28  8 3  2 5  2 31  7
Healthy children 10–16 y (n  6) 26  11 7  4 25  5 3  1 5  2 35  13
XLA1 (LWBM) 15 0.2 55 6 5 20
XLA2 (thawed BMMC) 8 0.2 39 15 11 26
XLA3 (thawed BMMC) 40 0.01 22 11 3 13
XLA4 (thawed BMMC) 21 0.04 38 6 6 22
XLA5 (thawed BMMC) 39 0.2 23 12 5 17
XLA6 (LWBM) 12 0.03 68 5 7 15
XLA7 (thawed BMMC) 20 0.03 52 16 2 6
XLA8 (LWBM) 9 0.1 56 6 3 25
XLA9 (LWBM) 26 2.2 29 7 5 34
* Percentage of precursor B cells was calculated by subtracting the percentage of mature B cells from the total percentage of CD22 B cells.
† Percentage of mature B cells was based on the CD10/SmIgM or SmIgM/SmIgD populations (labelings 6 and 7 from Table 1).
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the splice site sequences could be evaluated as well. All
sequencing was performed as described before (32) and run on
an ABI Prism 377 fluorescent sequencer (Applied Biosystems).
Isolation of PCR products from agarose gels. RT-PCR
products from XLA patient 9 were separated in a 1% agarose
gel stained with ethidium bromide. Under UV illumination,
two bands of different sizes were cut out of the gel and frozen
for 15 min at 20°C. After thawing, the PCR products were
isolated from the gel fragments using ultrafree-mc Millipore
columns (Millipore Corporation, Bedford, MA, U.S.A.) ac-
cording to the manufacturer’s instructions and used directly for
fluorescent sequencing.
Figure 2. Flow cytometric analysis of BM samples from a healthy child and nine XLA patients, showing the normal composition of the precursor B-cell
compartment and the differentiation arrests in XLA patients. The composition of the precursor B-cell compartment in the healthy child was representative of that
in all other healthy children (n  19). The composition of the precursor B-cell compartment was analyzed within a lymphogate and a CD22 (A) or CD19
histogram gate (B and C). The order of the B-cell differentiation stages in the healthy child is indicated with arrows. In general, XLA patients lacked or showed
a severe reduction in the more mature B-cell differentiation stages with a relative increase in the immature B-cell differentiation stages.
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RESULTS
Composition of the BM lymphogate. To characterize B-cell
development in young children, BM samples from 19 healthy
children and nine XLA patients were analyzed by flow cytom-
etry, using 14 triple labelings (Table 1). The obtained percent-
ages of CD22 B cells in the BM lymphogate are shown in
Table 2. This table illustrates the variation in composition of
the lymphogate. This variation is caused by contamination of
the lymphogate with T lymphocytes, NK cells, myeloid pre-
cursors, and normoblasts (Table 2). Therefore, reliable com-
parison of B-cell subpopulations in BM samples from healthy
children and XLA patients requires analysis within a B-cell
gate.
The use of CD22 as a pan-B-cell marker has been described
previously (33, 34). To confirm the reliability of this marker we
performed quadruple labelings using a mixture of PerCP-
Cy5.5–labeled MAbs (CD3, CD33, and CD16) together with
CD22. Analyses of BM samples from two healthy children
showed that CD22 is rarely expressed on CD3 T cells,
CD33 myeloid cells, or CD16 NK cells (Fig. 1), thereby
excluding the possibility that the CD22 gate would include
substantial numbers of non-B lineage cells. Furthermore, la-
belings containing both CD22 and CD79a showed a small
CD22/CyCD79a pro-B-cell population (data not shown).
Therefore, we choose CD22 as a pan-B-cell marker instead of
CyCD79a.
B-cell subsets in bone marrow from healthy donors. The
markers CD22 and CD19 were used to identify the total B-cell
population in BM, because these two markers are regarded as
pan-B-cell markers, which are expressed by virtually all pre-
cursor B cells. In each triple labeling, the expression pattern of
the two other MAbs was analyzed within the CD22 or CD19
gate, resulting in normal differentiation pathways (Fig. 2). The
apparent heterogeneity of the CD22 gate in Figure 2A was
caused by different expression levels (CD22 and CD22bright)
on precursor B-cells, which was also clear from Figure 1.
Virtually all events within the B-cell gates were grouped
using different regions, bringing the total percentage of iden-
tified B-cell subpopulations in each gate to approximately
100%. For example, the CyIg-SmIgM-CD19 labeling was
analyzed within the CD19 gate (Fig. 2B). Three subpopulations
could be distinguished (from immature to mature): CyIg/
SmIgM, CyIg/SmIgM, and CyIg/SmIgM. An iden-
tical approach was followed for other markers within the CD22
or CD19 gates of all 14 triple labelings, resulting in the
differentiation scheme in Table 3.
Several human B-cell differentiation schemes with five to six
precursor B-cell subsets have been published (18–22). Pro-B,
pre-B, immature B, and mature B cells were designated ac-
cording to Ghia et al. (21). The CD19 fraction was termed
pro-B cells, and was further subdivided on the basis of TdT
expression. Pre-B-I cells were defined as CD19, CD10,
TdT, CD34, and CyIg and were further subdivided on
the basis of the level of CD10 expression. Pre-B-II cells were
CD19, CD10, TdT, CD34, and CyIg, and were fur-
ther subdivided on the basis of the presence or absence of
CD20 expression. Immature B cells were CD19, CD10,
SmIgM, and SmIgD, whereas mature B cells were CD19,
CD10, SmIgM, and SmIgD.
All percentages of precursor-B cell subpopulations in
healthy children within a CD22 or CD19 gate are listed in
the lower part of Table 3. It has been published that the relative
composition of the precursor B-cell compartment is age related
with several differences between children and adults (22). We
Figure 2. C.
163BONE MARROW COMPOSITION IN XLA PATIENTS
subdivided the healthy children into three age groups to check
for differences among children of different age groups. Our
results showed only minor nonsignificant differences in the
composition of the precursor B-cell compartment in BM from
children of different age groups.
Definition of CD22 and CD19 B-cell compartments. We
identified the entire B-cell compartment as being CD22. In
healthy children younger than 5 y of age, between 5 and 10 y
of age, and between 10 and 16 y of age, the CD19 fraction
within this CD22 B-cell compartment was very large (label-
ings 1 and 8), i.e. 91.4%, 88.7%, and 90.9%, respectively,
implying that the CD19/CD22 pro-B-cell population was
small in all three age groups (Table 3). Consequently, the
percentages of the different subpopulations within the CD19
gate could be recalculated into percentages of the CD22
population, by multiplying with 0.914, 0.887, and 0.909, re-
spectively. The same approach was followed for XLA patients.
Correction of the B-cell compartment in BM for blood
contamination. The mature B-cell population (stage 8) varied
between healthy children mainly because of blood contamina-
tion with CD10/SmIgM/SmIgD B-lymphocytes: 1–30%
within the lymphogate (Table 2) and 8–42% within the
CD19 gate. This variable degree of blood contamination was
also clear from the comparable variation of CD3 T lympho-
cytes within the lymphogate, ranging from 9 to 35% (Table 2).
To correct for this variance in our comparative studies between
precursor B cells in normal BM and in BM from XLA patients,
we excluded the mature CD10/SmIgM/SmIgD B-cell pop-
ulation from our calculations (Table 2). Consequently, the
percentages of stages 1–7 were recalculated to 100% (Fig. 3).
From this recalculation, the percentages of precursor B cells in
Table 2 were set to 100%.
Patient characteristics and mutations in the BTK gene.
The nine boys were clinically diagnosed as XLA on the basis
Figure 3. Composition of the precursor B-cell compartment in healthy
children (A) compared with XLA patients (B), corrected for the composition of
the lymphogate. The precursor B-cell compartment (Table 2) was set to 100%.
To this aim, CD10/SmIgM/SmIgD mature B cells were excluded (see text
for details). Seven of nine XLA patients showed a similar differentiation arrest
with approximately 80% of the precursor B cells in the pro-B and pre-B-I
stages, thereby revealing an arrest at the transition from CyIg to CyIg
pre-B cells, with a variable degree of leakiness. XLA patients 2 and 9 showed
different compositions of their precursor B-cell compartments.
Table 3. B-cell differentiation stages in BM from healthy children (16 y)
1 2 3 4 5 6 7 8
Immunologic markers Pro-B Pre-B-I Pre-B-II Immature B Mature B
CD19      
CD22        
CD34        
TdT        
CD10        
CD20        
CD38 NA NA      
CyIgM        
SmIgM        
SmIgD        
Mean % within
CD22 gate (SD)
5 y (n  6) 6.0 (1.7) 1.2 (1.4) 7.6 (4.0) 83.8 (7.0)
5–10 y (n  7) 8.2 (4.8) 1.0 (0.6) 9.1 (1.5) 79.7 (6.2)
10–16 y (n  6) 6.8 (2.2) 0.8 (0.3) 8.3 (3.1) 82.6 (4.6)
Mean % within
CD19 gate (SD)
5 y (n  6)  3.7 (2.4) 3.2 (2.3) 23.2 (16.3) 22.4 (5.0) 19.6 (8.0) 25.6 (14.0)
5–10 y (n  7)  4.6 (1.4) 4.9 (2.1) 34.8 (12.7) 18.2 (4.7) 15.2 (3.2) 24.4 (11.5)
10–16 y (n  6)  5.7 (2.3) 4.9 (3.1) 25.8 (8.0) 20.4 (6.7) 18.1 (3.8) 28.8 (13.4)
NA  not analyzed. Because CD38 was not used in combination with CD22 (Table 1), no precise information about CD38 expression on pro-B cells was
available. However, analysis of CD34 and CD38 expression in the lymphogate showed that 99% of CD34 cells were also CD38. Hao et al. (53) showed
that the CD38 population comprised 3.53%  0.68% of the CD34 cells.
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of hypo- or agammaglobulinemia (35) and strongly reduced or
undetectable numbers of mature B lymphocytes in the PB.
Analysis of PB mature B lymphocytes for SmIgM/SmIgD
expression showed that XLA patients 1, 4, 5, and 7 had very
low percentages (0.1% of lymphocytes) of SmIgM/
SmIgD B lymphocytes. In XLA patients 3 and 6, no SmIg
B lymphocytes could be detected. XLA patient 2 had 0.6%
SmIgM//SmIgD B lymphocytes at the age of 6 y 5 mo,
whereas XLA patient 8 had 0.3% SmIgM/SmIgD B lym-
phocytes at the age of 6 y 7 mo. XLA patient 9 was diagnosed
at 8 y of age and had 1.0% of SmIgM//SmIgD B
lymphocytes in the PB and almost normal levels of IgG and
IgA, but decreased levels of IgM (Table 4).
Mutation analysis of the BTK gene was performed at the
DNA level. We found five point mutations, one splice site
mutation, two small deletions, and one insertion. Five muta-
tions (XLA patients 1, 4, 5, 6, and 7) had already been
observed in other patients (5, 36–41), whereas the other four
mutations (XLA patients 2, 3, 8, and 9) were previously
unknown. The entire BTK gene of each patient was sequenced
to exclude additional mutations. The predicted effects of these
mutations on the protein level are summarized in Table 4.
Except for XLA patient 9, all BTK mutations would lead to
absence of functional BTK proteins, either because of aa
substitutions in the BTK kinase domain or because of prema-
ture stop codons.
In XLA patient 9, the last nucleotide of exon 3 was mutated.
This mutation did not give rise to an aa substitution. However,
RT-PCR analysis on mRNA from PB granulocytes generated
two bands of different sizes, which were isolated and se-
quenced. We identified a dominant mutated form of BTK
mRNA with 106 nucleotides inserted from intron 3, but also
low levels of wt BTK mRNA (Fig. 4). Quantitative analysis by
real-time quantitative PCR with TaqMan technology of wt
BTK mRNA expression in PB granulocytes of this patient
indicated that 5% of normal levels were present (data not
shown).
Flow cytometric analysis of BM precursor B cells from
XLA patients. Because of lack of BM cells, a few triple
labelings could not be performed in some XLA patients.
Particularly labeling 7 (SmIgD/SmIgM/CD19) could not be
performed on BM samples from XLA patients 2, 3, 4, and 7. In
these four XLA patients we used the CD10/SmIgM popu-
lation to identify mature B cells. In five XLA patients we used
thawed BMMC because no fresh BM samples were available
(see “Methods”).
In BM from healthy children, approximately 20% of the
B-cell compartment consisted of CyIg precursor B cells,
equally distributed over pro-B cells and pre-B-I cells (pro-B/
pre-B-I ratio of 1.2  0.8), whereas in BM from eight of nine
XLA patients approximately 80% (71–92%) of the B-cell
compartment was located in these stages (Fig. 3). Therefore,
our results indicate that the differentiation arrest in the eight
XLA patients resulted in a 4-fold relative accumulation of
B-cell subpopulations located before the transition from
CyIg to CyIg pre-B cells. The relative accumulation of
CyIg precursor B cells was somewhat lower for pro-B cells
(18–42%) compared with pre-B-I cells (34–63%; Fig. 3B),
resulting in a mean pro-B/pre-B-I ratio of 0.6 0.3 in seven of
the eight XLA patients. Although this differentiation arrest was
Figure 4. RT-PCR analysis of BTK mRNA from PB granulocytes of XLA
patient 9 and three healthy male control children. XLA patient 9 predominantly
expressed the mutated form (upper band) with 106 nucleotides inserted from
intron 3. Small amounts of wt BTK mRNA (lower band) could be detected.
Table 4. Characteristics of XLA patients
Patient
Age at
diagnosis*
Serum Ig levels at diagnosis† Age at
BM
puncture
Genomic mutation‡ Predicted effect at protein level
IgM
(g/L)
IgG
(g/L)
IgA
(g/L) Exon Nucleotide Amino acid Affected domain
XLA1 0 y 7 mo 0.11 0.3 0.01 0 y 7 mo 17 C53T R562W Kinase
XLA2 1 y 2 mo 0.26 0.27 0.17 1 y 3 mo 7 26delG L198stop TH
XLA3 1 y 9 mo 0.1 0.36 0.1 1 y 9 mo 2 142delTC Y40stop PH
XLA4 0 y 7 mo 0.13 0.41 0.04 1 y 10 mo 15 G78A M509I Kinase
XLA5 1 y 10 mo 0.13 0.01 0 1 y 11 mo 15 C106A Y485stop Kinase
XLA6 2 y 11 mo 0.05 0.1 0.06 2 y 11 mo 3 75insA E84stop PH
XLA7 1 y 8 mo NA 0.3 NA 5 y 3 mo 14 C98A Y425stop Kinase
XLA8 6 y 7 mo 0.1 3.0 0.05 6 y 7 mo 18 T10C M587T Kinase
XLA9§ 8 y 4 mo 0.05 4.7 0.4 8 y 5 mo 3 G99A L119stop PH
* XLA diagnosis was based on strongly reduced or absent numbers of B lymphocytes in the PB and hypogammaglobulinemia.
† Lower level normal serum Ig values according to Cejka et al. (35): 5–12 mo: IgM 0.47, IgG 4.34, IgA 0.15; 1–2 y: IgM 0.39, IgG 3.69, IgA 0.15; 2–3 y:
IgM 0.53, IgG 5.10, IgA 0.25, 6–9 y: IgM 0.54, IgG 6.83, IgA 0.32.
† The beginning of each exon is numbered as 1.
§ Mutation in donor splice site of exon 3 with mutant and wt BTK mRNA detectable.
NA  not analyzed.
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virtually identical in seven of the eight XLA patients, the
percentage of B-cell subpopulations located behind the arrest
(CyIg pre-B-II cells and immature B cells) was variable,
indicating leakiness (Fig. 3B).
Of the eight XLA patients with absence of functional BTK
proteins, only XLA patient 2 displayed an atypical differenti-
ation pattern with 73% CD19/CD22 pro-B cells and 10%
pre-B-I cells (pro-B/pre-B-I ratio of 7.4). Apparently, in this
patient a major differentiation arrest was located at a very early
stage, i.e. at the transition from pro-B cells to CyIg pre-B-I
cells (Fig. 3B). However, the SmIgM B-cell population was
extensive compared with other XLA patients, suggesting a
second arrest at the transition from immature SmIgM to
mature SmIgM/SmIgD B cells.
XLA patient 9 showed an apparently normal composition of
the precursor B-cell compartment. Nevertheless, this patient
had diminished percentages of mature B cells in his BM (Table
2) and in his PB.
In general, seven of the eight XLA patients with absence of
functional BTK proteins showed a similar differentiation arrest
at the transition from CyIg to CyIg pre-B cells, with a
variable degree of leakiness (Fig. 3B).
Atypical B-cell differentiation patterns in BM from XLA
patients. In BM samples from healthy children, coexpression
of the markers CD34 and CD20 was virtually absent (Table 3),
as 4.4% CD34/CD20 cells were detectable (Fig. 5). How-
ever, in BM from most XLA patients a substantial CD34/
CD20/CD19 population could be identified. This atypical
B-cell population varied among XLA patients from 11 to 20%,
but was smaller (6%) in XLA patient 9. The atypical marker
expression was predominantly caused by prolonged expression
of CD34, because in BM samples from XLA patients 9–16%
of CyIg pre-B-II cells was CD34 (4% in XLA patient 9),
compared with 2.4% in healthy children (Fig. 5).
DISCUSSION
We have analyzed BM samples from 19 healthy children by
flow cytometry, using 14 triple labelings, revealing the normal
composition of the precursor B-cell compartment (Fig. 2). This
resulted in an accurate human B-cell differentiation scheme,
which resembles the classification according to Ghia et al. (21).
Our scheme, in which Ig expression patterns are dominant
variables, consists of eight consecutive stages and is summa-
rized in Table 3. Similar analysis of the composition of the
precursor B-cell compartment in BM from nine XLA patients
showed that approximately 80% (71–92%) of the B-cell com-
partment in eight of these patients consisted of CyIg pre-
cursor B cells (pro-B cells and pre-B-I cells), in contrast to
approximately 20% in healthy children. This is in line with the
results of Campana et al. (11), who described a maturation
arrest at the transition between CyIg and CyIg pre-B
cells in BM of XLA patients. The localization of this arrest at
the transition between CyIg and CyIg pre-B cells in
seven of the eight XLA patients with absence of functional
BTK proteins suggests that BTK proteins are required for the
expansion of the CyIg pre-B-II population by signaling via
the pre-BCR, which is expressed on CyIg pre-B cells (21,
42). This is supported by the finding that BTK is constitutively
phosphorylated in a pre-B-cell line, which implicates a func-
tional role for BTK in pre-BCR signaling during B-cell devel-
opment (43).
B-cell differentiation arrests have been analyzed in BM
samples from patients with non-X-linked causes of agamma-
globulinemia. These patients have mutations in genes that
encode other components of the pre-BCR, such as the  heavy
chain or 5/14.1 (44, 45), or in genes that encode proteins
involved in signaling via the pre-BCR, such as CD79a or
B-cell linker protein (BLNK) (46, 47). BLNK is an adapter
protein, which plays a role in the same signal-transduction
Figure 5. Flow cytometric analysis of CD34/CD20 coexpression within the CD19 lymphogate of BM from a healthy child and three XLA patients. In all
healthy children the markers CD34 and CD20 were virtually exclusive (CD34/CD20 population, stage 5). However, most XLA patients showed a dominant
CD34/CD20 population (upper panel). This CD34/CD20 population originated from prolonged CD34 expression, inasmuch as in XLA patients a large
proportion of CyIg pre-B-II cells was also CD34 (lower panel). XLA patients 2 and 5 showed the smallest and largest CD34/CyIg populations,
respectively. XLA patient 1 was selected as a representative example of all other XLA patients (except for XLA patient 9).
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pathway as BTK (48). The B-cell differentiation arrest in BM
from these non-XLA patients seems to be comparable to the
arrest in XLA patients and is also located at the transition from
CyIg pre-B-I cells to CyIg pre-B-II cells (49). These
results strongly support a role for BTK at the pre-BCR check-
point in human B-cell development.
The flow cytometric data of the XLA patients clearly show
a relative accumulation of CyIg precursor B cells, particu-
larly of pre-B-I cells (Fig. 3B). This is in contrast with the
studies by Campana et al. (11), who described normal frequen-
cies of CyIg precursor B cells, and Pearl et al. (10), who
described normal frequencies of CyIg precursor B cells in
their XLA patients. These discrepancies are probably related to
differences in techniques and in age of the studied patients. Our
results are in line with the study by Nomura et al. (15), who
described significantly increased percentages of precursor B
cells located before the blockade.
We hypothesized that accurate characterization of the B-cell
differentiation arrest in BM of XLA patients would help to
explain the level of immunologic variation previously reported
(10, 11). In seven of the eight XLA patients with absence of
functional BTK proteins, this differentiation arrest appeared to
be very similar, with a large CyIg precursor B-cell com-
partment and a more prominent accumulation of pre-B-I cells
compared with pro-B-cells, resulting in a pro-B/pre-B-I ratio of
0.6  0.3, which is significantly lower (Mann-Whitney U test
for unrelated groups with unequal SDs; p  0.03) than in
normal BM (1.2  0.8). Although the arrest was similar, the
degree of leakiness, indicated by the percentage of B-cell
subpopulations located behind the arrest, varied among these
seven XLA patients (Fig. 3B). The age of the XLA patients was
comparable and the percentage of myeloid cells in the lym-
phogate did not differ significantly between patients, indicating
that none of the patients suffered from infections at the time of
BM donation. It seems therefore most likely that other genetic
factors influence the degree of leakiness, as has also been
suggested with respect to the heterogeneity of the clinical
picture of XLA (7, 8).
In the eighth XLA patient (XLA-2), the CyIg precursor
B-cell compartment mainly consisted of pro-B cells (pro-B/
pre-B-I ratio of 7.4). This particularly concerned the most
immature CD22/CD19/TdT pro-B cells (stage 1), which
represented 66% of the total precursor B-cell compartment in
this patient (Figs. 2A and 3B). Curiously, the percentage of
SmIgM B cells was also increased in this patient compared
with other XLA patients, indicating a second arrest at the
transition from immature to mature B cells. We do not have an
explanation for this unique composition of the precursor B-cell
compartment.
It is interesting to note that the precursor B cells of XLA
patient 9, which can generate low levels of wt BTK mRNA
(Fig. 4), apparently can overcome the differentiation arrest at
the pre-BCR level, as CyIg pre-B-II cells were present in
near normal frequencies in the BM of this patient (Fig. 3B).
However, the reduced numbers of mature B lymphocytes in the
PB of this patient indicate that the differentiation arrest at the
BCR level is more severe. This means that if BTK proteins are
indeed involved in signaling via the pre-BCR, lower amounts
of BTK are needed for signal transduction from the pre-BCR
compared with the BCR. The phenotype of this patient resem-
bles that of X-linked immunodeficiency mice, which have a
point mutation in the pleckstrin homology domain or a targeted
deletion of BTK. These mice show normal precursor B-cell
compartments in BM, but reduced numbers of mature B lym-
phocytes in PB, and predominantly lack IgM and IgG3 in the
serum (50–52).
The marker expression on precursor B cells in BM samples
from the seven similar XLA patients seemed to be normal until
the pre-B-II stage, in which CyIg is expressed, was reached.
The markers CD34 and CD20 showed virtually no coexpres-
sion in healthy children, but were coexpressed in these XLA
patients, resulting in a clearly detectable CD34/CD20/
CD19 population (Fig. 5). The coexpression appeared to be
caused by prolonged CD34 expression, as a large proportion of
CyIg pre-B-II cells was CD34. This suggests that nor-
mally CD34 down-regulation is mediated via pre-BCR
signaling.
In conclusion, the B-cell differentiation arrest in the majority
of XLA patients appeared to be homogeneous, with approxi-
mately 80% of the precursor B-cell compartment being nega-
tive for CyIg expression. The size and nature of the residual
more mature B-cell population (leakiness) varied among pa-
tients, independent of the type of BTK mutation. Furthermore,
it appears that the composition of the precursor B-cell com-
partment in BM of some XLA patients can be influenced by
low levels of wt BTK mRNA, as was particularly illustrated by
XLA patient 9. It would be interesting to analyze the presence
of wt BTK mRNA levels in other XLA patients with splice site
mutations in the BTK gene. Because low levels of wt BTK
mRNA appear to be sufficient for a seemingly normal compo-
sition of the precursor B-cell compartment, one might expect
more mature B lymphocytes in the PB and higher serum Ig
levels in these patients.
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